Sonazoid与SonoVue超声造影诊断肝癌的非劣效性研究
这项前瞻性单中心非劣效性研究纳入105例有肝癌风险的参与者,对比Sonazoid超声造影(SZUS)与SonoVue超声造影(SVUS)在相同诊断标准下诊断肝细胞癌(HCC)的准确性。结果显示,采用5分钟廓清标准时,SZUS的每病灶准确率(72.4%)非劣效于SVUS(71.4%),且将廓清延迟从5分钟延长至10分钟并未显著改善HCC诊断。
要点
- Sonazoid超声造影诊断HCC的准确率非劣效于SonoVue超声造影。
- 采用5分钟廓清标准时,两者诊断准确率差异为0.95%p(95%CI -3.8%p-5.7%p)。
- 延长廓清观察时间至10分钟以上未显著提高HCC诊断敏感度或特异度。
核心结论
- 在相同诊断标准下,Sonazoid超声造影诊断HCC非劣效于SonoVue超声造影。
- 将廓清时间延迟从5分钟延长至10分钟以上,未显著改善HCC诊断效能。
研究设计与样本
- 前瞻性、单中心、自身对照非劣效性研究(NCT04847726),纳入105例有肝癌风险的参与者(71例男性,平均年龄63±11岁,范围26-86岁)。
- 所有参与者同日接受Sonazoid超声造影(实验方法)和SonoVue超声造影(对照方法),每位参与者选取一个代表性病灶进行评估。
- 图像由三名阅片者(操作者及两名独立阅片者)判读;所有恶性病灶经组织病理学诊断,良性病灶经随访稳定性或病理证实。
- 主要终点为采用传统超声造影诊断标准(动脉期高增强后出现轻度廓清(注射造影剂后2分钟内评估)和晚期廓清(≥60秒,延迟5分钟))时,三名阅片者合并的每病灶诊断准确率,非劣效界值为-10%p。
诊断标准与关键数值
- 传统超声造影诊断标准:动脉期高增强后出现轻度(注射后2分钟内评估)和晚期(≥60秒,延迟5分钟)廓清。
- 采用5分钟廓清标准时,SZUS的每病灶准确率(三名阅片者合并)为72.4%(95%CI 64.1%-79.3%),SVUS为71.4%(95%CI 63.1%-78.6%),差异为0.95%p(95%CI -3.8%p-5.7%p),满足非劣效性统计标准。
- 动脉期高增强联合5分钟廓清标准与>10分钟廓清标准的敏感度相同(59.0% vs. 59.0%,p=0.989),特异度无显著差异(90.9% vs. 86.4%,p=0.072)。
临床应用与阅片要点
- 在临床实践中,Sonazoid超声造影可作为SonoVue超声造影的替代选择,用于有肝癌风险患者的HCC诊断。
- 采用5分钟廓清标准即可,无需常规延长观察至10分钟以上以评估廓清。
局限性
- 研究为单中心设计,可能存在选择偏倚。
- 样本量有限(105例病灶),结论需更大规模多中心研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine whether Sonazoid-enhanced ultrasound (SZUS) was noninferior to SonoVue-enhanced ultrasound (SVUS) in diagnosing hepatocellular carcinoma (HCC) using the same diagnostic criteria.
MATERIALS AND METHODS: This prospective, single-center, noninferiority study (NCT04847726) enrolled 105 at-risk participants (71 male; mean age ± standard deviation, 63 ± 11 years; range, 26-86 years) with treatment-naïve solid hepatic nodules (≥ 1 cm). All participants underwent same-day SZUS (experimental method) and SVUS (control method) for one representative nodule per participant. Images were interpreted by three readers (the operator and two independent readers). All malignancies were diagnosed histopathologically, while the benignity of other lesions was confirmed by follow-up stability or pathology. The primary endpoint was per-lesion diagnostic accuracy for HCC pooled across three readers using the conventional contrast-enhanced ultrasound diagnostic criteria, including arterial phase hyperenhancement followed by mild (assessed within 2 minutes after contrast injection) and late (≥ 60 seconds with a delay of 5 minutes) washout. The noninferiority delta was -10%p. Furthermore, different time delays were compared as washout criteria in SZUS, including delays of 2, 5, and > 10 minutes.
RESULTS: A total of 105 lesions (HCCs [n = 61], non-HCC malignancies [n = 19], and benign [n = 25]) were evaluated. Using the 5-minutes washout criterion, per-lesion accuracy of SZUS pooled across the three readers (72.4%; 95% confidence interval [CI], 64.1%-79.3%) was noninferior to that of SVUS (71.4%; 95% CI, 63.1%-78.6%), meeting the statistical criterion for non-inferiority (difference of 0.95%p; 95% CI, -3.8%p-5.7%p). The arterial phase hyperenhancement combined with the 5-minutes washout criterion showed the same sensitivity as that of the > 10-minutes criterion (59.0% vs. 59.0%, p = 0.989), and the specificities were not significantly different (90.9% vs. 86.4%, p = 0.072).
CONCLUSION: SZUS was noninferior to SVUS for diagnosing HCC in at-risk patients using the same diagnostic criteria. No significant improvement in HCC diagnosis was observed by extending the washout time delay from 5 to 10 minutes.
引用
- Kang, Lee, Yoon, et al. Sonazoid™ versus SonoVue® for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study. Korean J Radiol. 2022. PMID: 36196767. doi:10.3348/kjr.2022.0388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。